SCHEMBL350730

SCHEMBL350730

COc1ccc(C2Oc3cc(O[C@@H]4O[C@H](C(=O)O)[C@@H](O)[C@H](O)[C@H]4O)cc(O)c3CC2O)cc1O

nearest known ligand 0.51

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
KDM1A O60341 2/20 0.51
SYNJ2 O15056 2/20 0.49
MEN1 O00255 3/20 0.47
KMT2A Q03164 3/20 0.47
POLB P06746 3/20 0.47
TDP1 Q9NUW8 2/20 0.47
CALM1 P0DP23 1/20 0.47
GSK3B P49841 1/20 0.47
CACNA1B Q00975 1/20 0.47
APBA1 Q02410 1/20 0.47
CTDSP1 Q9GZU7 1/20 0.47
PTGS1 P23219 3/20 0.47
CYP3A4 P08684 2/20 0.47
MAPK1 P28482 2/20 0.47
MAPK14 Q16539 1/20 0.47
BACE1 P56817 4/20 0.47
KDM4E B2RXH2 4/20 0.47
GAA P10253 3/20 0.47
PKM P14618 2/20 0.47
HSD17B10 Q99714 2/20 0.47

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL30217486 0.95 SYNJ2 (0.49) KDM1ASYNJ2MEN1KMT2APOLB
SCHEMBL17938831 0.95 SYNJ2 (0.49) KDM1ASYNJ2MEN1KMT2APOLB
SCHEMBL17938778 0.91 SYNJ2 (0.59) SYNJ2MEN1KMT2APOLBTDP1
SCHEMBL347773 0.91 SYNJ2 (0.59) SYNJ2MEN1KMT2APOLBTDP1
SCHEMBL25390204 0.90 BACE1 (0.53) SYNJ2MEN1KMT2APOLBTDP1
SCHEMBL14686056 0.90 BACE1 (0.53) SYNJ2MEN1KMT2APOLBTDP1
SCHEMBL14686099 0.90 BACE1 (0.53) SYNJ2MEN1KMT2APOLBTDP1
SCHEMBL14686199 0.90 BACE1 (0.53) SYNJ2MEN1KMT2APOLBTDP1
SCHEMBL30933022 0.89 PTGS1 (0.61) KDM1ASYNJ2TDP1PTGS1MAPK14
SCHEMBL14700129 0.88 BACE1 (0.57) SYNJ2MEN1KMT2APOLBTDP1

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 7 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
WO-2009135918-A1 COMPOSITIONS AND PROCESSES FOR PREPARING THEM CORESSENCE LIMITED (GB) 2009-11-12 WO claimed
US-20120015053-A1 TREATMENT OF PSORIASIS SCHMITZ HAROLD H (US) 2012-01-19 US disclosed
US-20110257119-A1 Microcirculation improvement and/or treatment SCHMITZ HAROLD 2011-10-20 US disclosed
WO-2009135918-A1 COMPOSITIONS AND PROCESSES FOR PREPARING THEM CORESSENCE LIMITED (GB) 2009-11-12 WO disclosed
US-20080090898-A1 Boosting immunity MARS, INCORPORATED (US) 2008-04-17 US disclosed
US-20080021097-A1 Arginase levels/activity REGENTS OF THE UNIVERSITY OF CALIFORNIA, THE 2008-01-24 US disclosed
US-20060293259-A1 Compositions and methods of use of derivatized flavanols MARS, INCORPORATED (US) 2006-12-28 US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (5 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20120015053-A1 TREATMENT OF PSORIASIS ARG1, ARG2, NOS2 KDM1A 379/4885SYNJ2 2676/4885MEN1 4463/4885
US-20110257119-A1 Microcirculation improvement and/or treatment TEK, SLC2A4, SLC2A8 KDM1A 2481/4885SYNJ2 2026/4885MEN1 2398/4885
US-20080090898-A1 Boosting immunity TLR7, TLR1, MYD88 KDM1A 919/4885SYNJ2 2909/4885MEN1 3084/4885
US-20080021097-A1 Arginase levels/activity ARG1, ARG2, MPO KDM1A 463/4885SYNJ2 3221/4885MEN1 3508/4885
US-20060293259-A1 Compositions and methods of use of derivatized flavanols F2, PIGS, PIGO KDM1A 182/4885SYNJ2 701/4885MEN1 3213/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.